A study of spectrum and outcome of central nervous system complications associated with immune checkpoint inhibitors
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications CNS disorders; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- 27 Nov 2020 New trial record